FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, particularly to ophthalmology. One of the objects is using 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diole (compound A), its separate isomers and a mixture of the same isomers, or pharmaceutically acceptable salts, solvates and hydrates thereof for preparing an agent for treating keratoplasty or refractive keratoplasty consequences. The second object is a method of treating the keratoplasty or refractive keratoplasty consequences in an individual in need thereof that involves administering a therapeutically effective amount of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diole (compound A), its separate isomers and mixtures of the same, pharmaceutically acceptable salts, solvates and hydrates thereof into the above individual.
EFFECT: invention provides treating the eye disorder consequences.
2 cl
Title | Year | Author | Number |
---|---|---|---|
LIQUID FORMULATIONS | 2006 |
|
RU2470631C2 |
LIQUID COMPOSITIONS | 2006 |
|
RU2428180C2 |
S1P RECEPTOR MODULATORS FOR MULTIPLE SCLEROSIS TREATMENT | 2007 |
|
RU2617502C2 |
SIP RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS | 2007 |
|
RU2495664C2 |
MODULATORS OF RECEPTOR S1P FOR TREATMENT OF MULTIPLE SCLEROSIS | 2007 |
|
RU2569732C9 |
COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
ORGANIC COMPOUNDS | 2004 |
|
RU2358716C2 |
METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475236C2 |
ORAL PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475237C2 |
USING SIP RECEPTOR MODULATOR | 2008 |
|
RU2498796C2 |
Authors
Dates
2013-11-10—Published
2006-03-02—Filed